CSAGE inhibitors, short for Cell Signaling and Growth Arresting Inhibitors, constitute a diverse class of chemical compounds designed to modulate cellular processes crucial for signal transduction, proliferation, and growth regulation in living organisms. These inhibitors are primarily employed in laboratory research settings and studies to dissect the intricate web of molecular interactions within cells. Their primary function is to interfere with specific intracellular signaling pathways, thereby allowing scientists to elucidate the roles of individual proteins and cascades in cell function and dysfunction.
CSAGE inhibitors encompass a wide range of chemical structures and mechanisms of action, making them versatile tools for cell biology and molecular research. These inhibitors often target key kinases and enzymes involved in signal transduction, including receptor tyrosine kinases, serine/threonine kinases, and downstream effectors. By selectively inhibiting these molecular players, CSAGE inhibitors enable researchers to dissect the intricacies of signaling networks, uncover targets, and gain valuable insights into the molecular underpinnings of various diseases. Moreover, these inhibitors can serve as indispensable tools for studying cellular processes such as cell cycle regulation, apoptosis, and differentiation, shedding light on fundamental aspects of cell biology. Overall, CSAGE inhibitors play a pivotal role in advancing our understanding of cellular signaling pathways and their dysregulation, laying the foundation for future interventions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits EGFR tyrosine kinase, blocking signaling pathways that promote cell growth and division in cancer cells. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets BCR-ABL tyrosine kinase, inhibiting its activity in chronic myeloid leukemia (CML) and other malignancies. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases involved in tumor angiogenesis and cell proliferation, often used for liver and kidney cancers. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Blocks MEK, a key component of the MAPK pathway, thereby inhibiting cell growth and division in various cancers. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Targets mTOR, a central regulator of cell growth and proliferation, often used in certain cancers. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR tyrosine kinase, disrupting signaling cascades responsible for promoting cancer cell survival and growth. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Targets both EGFR and HER2 kinases, impeding downstream signaling pathways involved in breast and other cancers. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Specifically targets mutated BRAF, which is often overactive in melanomas, thereby reducing cancer cell proliferation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Blocks BTK signaling in B-cell cancers, disrupting cell growth and survival pathways, especially in chronic lymphocytic leukemia. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits CDK4/6, arresting the cell cycle progression in hormone receptor-positive breast cancers and other tumors. | ||||||